文献速递骨软组织肉瘤与黑色素瘤

PERSARC预测模型:高危肢体软组织肉瘤治疗决策工具

A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).
PubMed 文献 · Eur J Cancer · 2017-08-08

PERSARC是首个纳入放疗与手术切缘等治疗因素的高危原发性肢体软组织肉瘤(ESTS)预测模型,基于5个国际肉瘤中心766例2000–2014年手术患者开发,预测3、5、10年总生存(OS)与局部复发累积发生率(CILR)。多因素分析显示年龄与肿瘤大小对OS有显著影响,接受放疗者OS与CILR均优于单纯手术者。内部验证校准良好,OS与CILR的C-index分别为0.677与0.696。

要点

  • PERSARC模型纳入放疗与手术切缘等治疗因素,预测ESTS术后3、5、10年OS与CILR。
  • 多因素Cox回归显示年龄与肿瘤大小对OS有显著影响。
  • 接受放疗者OS与CILR均优于单纯手术者;内部验证C-index OS 0.677、CILR 0.696。

核心结论

  • PERSARC模型首次将已知临床危险因素与不同治疗方式及手术结局指标结合,并经内部验证可对原发高危ESTS术后OS与CILR提供可靠预测。

研究设计与样本

  • 模型开发队列为2000–2014年间在五个国际专业肉瘤中心接受手术的766例ESTS患者。
  • 采用多因素Cox比例风险回归与Fine和Gray模型评估预后因素对OS及LR累积发生率(CILR)的影响。
  • 通过内部交叉验证与校准评估预测性能,以C-index确定区分度。

主要发现

  • 多因素Cox回归显示年龄与肿瘤大小对OS有显著影响。
  • 接受放疗的患者在OS与CILR方面均优于单纯手术者。
  • 内部验证显示校准良好,OS与CILR的C-index分别为0.677与0.696。

关键数值与推荐

  • OS的C-index为0.677,CILR的C-index为0.696。
  • 模型预测术后3、5、10年的OS与LR概率。
  • 证据水平为level III。

临床怎么用

  • PERSARC模型可用于支持高危ESTS患者的共享决策,整合治疗方式与手术结局指标预测术后OS与CILR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To support shared decision-making, we developed the first prediction model for patients with primary soft-tissue sarcomas of the extremities (ESTS) which takes into account treatment modalities, including applied radiotherapy (RT) and achieved surgical margins. The PERsonalised SARcoma Care (PERSARC) model, predicts overall survival (OS) and the probability of local recurrence (LR) at 3, 5 and 10 years. AIM: Development and validation, by internal validation, of the PERSARC prediction model. METHODS: The cohort used to develop the model consists of 766 ESTS patients who underwent surgery, between 2000 and 2014, at five specialised international sarcoma centres. To assess the effect of prognostic factors on OS and on the cumulative incidence of LR (CILR), a multivariate Cox proportional hazard regression and the Fine and Gray model were estimated. Predictive performance was investigated by using internal cross validation (CV) and calibration. The discriminative ability of the model was determined with the C-index. RESULTS: Multivariate Cox regression revealed that age and tumour size had a significant effect on OS. More importantly, patients who received RT showed better outcomes, in terms of OS and CILR, than those treated with surgery alone. Internal validation of the model showed good calibration and discrimination, with a C-index of 0.677 and 0.696 for OS and CILR, respectively. CONCLUSIONS: The PERSARC model is the first to incorporate known clinical risk factors with the use of different treatments and surgical outcome measures. The developed model is internally validated to provide a reliable prediction of post-operative OS and CILR for patients with primary high-grade ESTS. LEVEL OF SIGNIFICANCE: level III.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Praag VM, Rueten-Budde AJ, Jeys LM, et al. A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC). Eur J Cancer. 2017. PMID: 28797949. doi:10.1016/j.ejca.2017.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。